Veliparib (ABT-888)

Catalog No.S1004 Synonyms: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 40 Publications

9 Customer Reviews

  • (A) OVCAR-8 cells were exposed to the indicated concentrations of FdUrd along with vehicle, 3 μM ABT-888 or 300 nM AZD2281 for 24 h. Following washing, ABT-888 and AZD2281 were re-added to the plates initially exposed to these agents, and cells were cultured in the continued presence of ABT-888 and AZD2281 for 8 d until colonies formed. (B) OVCAR-8 cells were exposed continuously to the indicated agents for 8 d. (C) OVCAR-8 cells treated as in (A) except that the indicated concentrations of ABT-888 were used.

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

    OVCAR-8 cells were plated, treated with indicated concentrations of FdUrd and 3 μM ABT-888 using the exposure schemes depicted in (C) and assayed for clonogenicity (D).

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046-1051. Veliparib (ABT-888) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

  • Colorimetric poly(ADP-ribose) polymerase (PARP) activity assay showing the relative activity of the PARP-1 enzyme in Raji lymphocyte tumor cells. Results show a highly significant difference in PARP activity in the controls [PBS and dimethyl sulfoxide (DMSO)] compared with 24 h incubation with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281. A significant increase in PARP enzyme activity is shown in DMSO-incubated cells compared with PBS control.* P < 0.05.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

    T47D breast cancer cells were pretreated with indicated concentrations of ABT-888

     

     

    Dr.Zhang of Tianjin Medical University. Veliparib (ABT-888) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor ABT-888 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor ABT-888 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    David Schrmann from University of Base. Veliparib (ABT-888) purchased from Selleck.

    Caption:  451 Lu is a melanoma cell line with high PARP expression that is resistant to temozolomide.  Treatment with 25 µM ABT-888 greatly increased sensitivity to temozolomide compared to cells without ABT-888 treatment as measured by MTS assay.

     

     

    Dr. Steve Reuland from University of Colorado Denver. Veliparib (ABT-888) purchased from Selleck.

  • Effect of ABT-888 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     
     

     

    Dr. Xiangbing Meng of University of Iowa. Veliparib (ABT-888) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 MYTLbY5ie2ViQYPzZZk> M3nDWVMxKG2rbh?= MXHJcohq[mm2aX;uJI9nKFCDUmCxJJdqfGhiRVO1NEBw\iByLkCwNkDPxE1? MX6xPVg5QDd4MB?=
Jurkat M3rFNWtqdmG|ZTDBd5NigQ>? NVXrOnFZQTZiaB?= M{\ON2ROW09? NX\jOWhGUW6qaXLpeIlwdiCxZjDQRXJROSCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yh[2WubDD2bYFjcWyrdImge4l1cCCHQ{WwJI9nKDNizszN Mn;KNlM5PTBzOUm=
Capan1 Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\EdFczKGh? M3P3WWROW09? MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFLSR2EzKGenbnWgcZV1[XSnZDDoeY1idiCFYYDhclEh[2WubIOge4l1cCCLQ{WwJI9nKDN7Lkeg{txO MVmyOFM6QDN6Mx?=
DT40 NYXkbnFrS3m2b4TvfIlkKEG|c3H5 MWe3NkBp MUTEUXNQ MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBkcGmla3XuJGJTS0F{LXTl[olkcWWwdDDEWFQxKGOnbHzz MU[yOFkzOjV6Nx?=
ML-1 M4H6fmFxd3C2b4TpZ{BCe3OjeR?= NV;5ZWJ6Oi53IN88US=> M{\yUVI1KGh? NXHqTW8yTE2VTx?= NWHLeYlZW3mwZYLnbZN1cWOjbHz5JIVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|IHnuJG1NNTFiY3XscJM> MnvrNlQ5QTVzM{W=
HCT-116 NF\1PFFMcW6jc3WgRZN{[Xl? MXiwMlUh|ryP NUXkRopDOjRiaB?= NFfrUVlRSVKSIHHjeIl3cXS7IHTlZ5Jm[XOncx?= NGjYNokzOzB3NEKxNy=>
UM-SCC1 MWXDfZRwfG:6aXOgRZN{[Xl? NWP3dHNpOTBizszN NF30dXEzPCCq M{C0dHJm\HWlZYOgeIhmKGOnbHygeoli[mmuaYT5 Mn36NlE6OTJ4MkC=
FaDu MoPaR5l1d3SxeHnjJGF{e2G7 M4jzTVExKM7:TR?= Mn\oNlQhcA>? M33Gb3Jm\HWlZYOgeIhmKGOnbHygeoli[mmuaYT5 M2PmZ|IyQTF{NkKw
PC-3 M4TmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrXcXVGOTBizszN NEDGZ|lKdmS3Y3XzJIEhe2mpbnnmbYNidnRiaX7obYJqfGmxbjDpckBkd2yxbomg[o9zdWG2aX;uxsA> M1XtWFIyPTdzOUGy
EoL-1-cell NULCfFJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPwPIoxUUN3ME2xMlA4QThizszN M3LPbnNCVkeHUh?=
NCI-SNU-5 NYrqb5pET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzGdJhKSzVyPUOuNVI5PDFizszN MWDTRW5ITVJ?
BV-173 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljkTWM2OD13LkS1OFA6KM7:TR?= NUf6NINnW0GQR1XS
HCC1806 NFzwfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjjRYNKSzVyPUWuO|UyPzNizszN MmLnV2FPT0WU
COLO-680 NGL0NVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrHTmFKSzVyPU[uNlE1ODZizszN MlLvV2FPT0WU
HCC2218 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTdwN{m3NFQh|ryP MYLTRW5ITVJ?
SK-MEL-24 NYPsVJc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[xfYhzUUN3ME23MlgyQTJ2IN88US=> NVXu[I9JW0GQR1XS
NCI-H720 NWqxZ2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRThwNEO2NFMh|ryP M2mzTHNCVkeHUh?=
KASUMI-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF35TYhKSzVyPUiuPFkzPjZizszN NHjMcHNUSU6JRWK=
HAL-01 MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTlwOEi2NkDPxE1? NVHIXlNvW0GQR1XS
CAL-33 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX0fFNKSzVyPUGwMlQ{PCEQvF2= NEDkO4xUSU6JRWK=
SK-MEL-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPJenBKSzVyPUGyMlQ3PjNizszN MnrhV2FPT0WU
Ramos-2G6-4C10 NUe4WFR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPzPZBKSzVyPUGyMlQ4PTJizszN NUO3Z|BCW0GQR1XS
KY821 MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fCN2lEPTB;MUKuOFg2KM7:TR?= MljIV2FPT0WU
HEC-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XKV2lEPTB;MUKuPVE6PiEQvF2= MlrxV2FPT0WU
SK-NEP-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX4TWM2OD1zMz6xOlYh|ryP NHnZW2FUSU6JRWK=
MN-60 MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF|LkWzPFkh|ryP MVvTRW5ITVJ?
DU-145 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTiTWM2OD1zMz65NFU{KM7:TR?= NIfBNWtUSU6JRWK=
EW-3 MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLaTWM2OD1zND61OVY2KM7:TR?= MnfjV2FPT0WU
OS-RC-2 NH\nWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF3Lkm1PFkh|ryP Mln3V2FPT0WU
RPMI-8226 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF4LkKwOFIh|ryP NHrrepBUSU6JRWK=
ChaGo-K-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHoc3JKSzVyPUG2MlU{OjVizszN NH;0UlVUSU6JRWK=
DEL MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInDVlVKSzVyPUG2MlY4OTdizszN MlfWV2FPT0WU
GP5d NF:3dFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\wXWRKSzVyPUG3MlA2OyEQvF2= NXrn[nVKW0GQR1XS
COLO-668 MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHVcoJKSzVyPUG3MlYzQTRizszN NFfOTJJUSU6JRWK=
H9 MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfLTWM2OD1zOD6yPFM{KM7:TR?= M4XrNnNCVkeHUh?=
NKM-1 NV7kO2lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfJdFdKSzVyPUG4MlUyOTlizszN NGOwO5ZUSU6JRWK=
KYSE-150 M1n1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF6Lkm5PFYh|ryP NHG0[WlUSU6JRWK=
Daoy NWGzc|AzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFeyepNKSzVyPUG5MlU3PDlizszN NFLBVo9USU6JRWK=
ECC10 NX\STJNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7XTWM2OD1{MD63OFU2KM7:TR?= M2fB[HNCVkeHUh?=
A388 NXnTenl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor2TWM2OD1{MT65NFkyKM7:TR?= NYP6Zo5tW0GQR1XS
MHH-NB-11 M2XlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PlOWlEPTB;MkOuNVM3OyEQvF2= M1\ETnNCVkeHUh?=
HCC1937 NGLTS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLleVUzUUN3ME2yOE44PDZizszN NHfye4hUSU6JRWK=
TGBC11TKB M3TnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXNTWM2OD1{NT62PFY{KM7:TR?= M3SydXNCVkeHUh?=
CTV-1 NYTsdXRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7CdI9KSzVyPUK1Mlg6PjlizszN M2fEb3NCVkeHUh?=
NCI-H2029 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4WwSWlEPTB;Mk[uOFI{QCEQvF2= NU\Ye|JjW0GQR1XS
HLE MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPEW4REUUN3ME2yO{4xPTRizszN MkTVV2FPT0WU
NCI-H1693 M4HNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJ5LkK4PVgh|ryP MYXTRW5ITVJ?
HCC70 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fwNGlEPTB;MkeuO|I1PiEQvF2= MlTwV2FPT0WU
BEN MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G3U2lEPTB;MkeuPVU3PiEQvF2= NGPYbGtUSU6JRWK=
LB771 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\zO|VKSzVyPUK4Mlg{PzNizszN Mn7uV2FPT0WU
697 NHjQfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHMS4RKSzVyPUK5MlAzOzVizszN NEDzXo5USU6JRWK=
LU-139 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mme4TWM2OD1{OT6zO|Q5KM7:TR?= MUnTRW5ITVJ?
EW-13 NWmy[ppLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PUNGlEPTB;MkmuN|gyPCEQvF2= MX;TRW5ITVJ?
MOLT-13 NGjBNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHJTWM2OD1{OT6zPFE1KM7:TR?= NWLoboRLW0GQR1XS
L-363 M37GSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLGWnJKSzVyPUK5MlQ4QThizszN MV7TRW5ITVJ?
EM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ7LkS5NFEh|ryP NUnpdY5PW0GQR1XS
RS4-11 M3zQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj4OlRmUUN3ME2zNE41OjRzIN88US=> MVnTRW5ITVJ?
A2780 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTvb5BKSzVyPUOwMlc1PTdizszN MlHQV2FPT0WU
KU812 NIDmUpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\jemFKSzVyPUOyMlM3PDJizszN MlizV2FPT0WU
COLO-684 M370Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fJWWlEPTB;M{OuN|U6QSEQvF2= MWrTRW5ITVJ?
MFE-280 NELCdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzJd2xjUUN3ME2zN{4{QDh7IN88US=> M4ruenNCVkeHUh?=
KG-1 NHG0PWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vEdmlEPTB;M{OuOlAxOSEQvF2= Ml60V2FPT0WU
JVM-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3rTWM2OD1|NT61PFY5KM7:TR?= MUjTRW5ITVJ?
MV-4-11 NIe1UIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DDNWlEPTB;M{WuPFQ6QSEQvF2= M3j0[HNCVkeHUh?=
LAMA-84 NUTpdZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfwS|NKSzVyPUO2Mlc{PDVizszN NYOxUWtwW0GQR1XS
MOLT-16 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PpfWlEPTB;M{[uPVUzKM7:TR?= NX\WT4lRW0GQR1XS
H4 M1H3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTN5LkW2O{DPxE1? M4XFXnNCVkeHUh?=
T47D MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN5LkewNVgh|ryP M3rJb3NCVkeHUh?=
CAL-54 NYTMeoJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf2fFZLUUN3ME2zO{46PjZizszN MUXTRW5ITVJ?
SW982 NYnndoNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn4N3RKSzVyPUO4MlA6QThizszN MUjTRW5ITVJ?
IGROV-1 NXHCe456T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPkTWM2OD1|OT6zN|A1KM7:TR?= MX3TRW5ITVJ?
NB14 MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XqZmlEPTB;NECuO|A{OSEQvF2= NIK4[2JUSU6JRWK=
HCC1187 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTRzLkK3O|Eh|ryP NYrWXo9rW0GQR1XS
SBC-1 NHvwWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;pfWlEPTB;NEGuN|A3OyEQvF2= M{TGN3NCVkeHUh?=
KARPAS-45 MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVexN|NiUUN3ME20NU41QDF6IN88US=> M3Hpc3NCVkeHUh?=
MOLT-4 Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jOZmlEPTB;NEKuNlU{QCEQvF2= NVrWbIQ4W0GQR1XS
JVM-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljJTWM2OD12Mj65NlA4KM7:TR?= MnrpV2FPT0WU
A4-Fuk M13YW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jCcGlEPTB;NEOuOVY6OSEQvF2= MoK2V2FPT0WU
MDA-MB-361 NXv0W2JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HQXWlEPTB;NEOuPFQyPCEQvF2= NFHXRo9USU6JRWK=
BALL-1 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HGOmlEPTB;NEOuPVU{OiEQvF2= MlHWV2FPT0WU
T98G MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n5SGlEPTB;NESuPFUyPyEQvF2= M4fIfXNCVkeHUh?=
Mo-T MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLqTWM2OD12NT62N|g6KM7:TR?= Ml\PV2FPT0WU
MHH-PREB-1 M17rbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTR3Lke1PFUh|ryP MUDTRW5ITVJ?
ALL-PO M1jOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDVPFRKSzVyPUS3MlM4QTFizszN NXrBWWlKW0GQR1XS
NCI-H510A M1S3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTR5LkmwN|Qh|ryP MlnrV2FPT0WU
ML-2 NEPTXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvDOGRRUUN3ME20PU44QDV4IN88US=> MVzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

+ Expand
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Formulation: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
Synonyms NSC 737664

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9, 2007 Phase 1
NCT03032614 Not yet recruiting Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio March 31, 2017 Phase 2
NCT01445522 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 3, 2008 Phase 1
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT02723864 Recruiting Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 22, 2016 Phase 1
NCT00994071 Completed Medulloblastoma|Pontine Glioma|Ependymoma|Astrocytoma|PNET National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 22, 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID